Genitourinary Cancers | Specialty

FDA Grants Nivolumab Breakthrough Designation for Advanced Bladder Cancer

June 28th 2016

The FDA has granted nivolumab (Opdivo) a breakthrough therapy designation for the treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen.

Troubles Ahead

June 25th 2016

Over the past few months, an alarming number of events have surfaced that we, as providers of oncologic urology care, should take notice.

Newly Approved Agents Alter RCC Landscape

June 23rd 2016

Thomas E. Hutson, DO, PharmD, discusses how nivolumab, cabozantinib, and lenvatinib/everolimus have significantly impacted the management of patients with renal cell carcinoma and promising combination regimens on the horizon to propel the field forward.

Expert Discusses Long-Term Survival, Next Steps With Nivolumab in RCC

June 15th 2016

David F. McDermott, MD, provides further insight on the long-term efficacy and safety of nivolumab and its role in renal cell carcinoma, as well as potential combination regimens and challenges with sequencing nivolumab.

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

June 14th 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

Cabozantinib Improves Survival in Renal Cell Carcinoma

June 9th 2016

Cabozantinib reduced the risk of death by 34% compared with everolimus in patients with previously treated advanced renal cell carcinoma, according to updated data from the phase III METEOR trial.

Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC

June 6th 2016

About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

June 6th 2016

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

A Look Ahead in Genitourinary Cancers

June 1st 2016

The Role of Biomarkers in Bladder Cancer

June 1st 2016

Measuring Response in Non-Muscle Invasive Bladder Cancer

June 1st 2016

Approaches in High-Risk Non-Muscle Invasive Bladder Cancer

June 1st 2016

Check Point Inhibition in Muscle-Invasive Bladder Cancer

June 1st 2016

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

June 1st 2016

First-Line Options in Muscle-Invasive Bladder Cancer

June 1st 2016

Abiraterone Plus Prednisone in CRPC: Factors to Consider

June 1st 2016

CRPC: Patient Selection in AR-Directed Therapies

June 1st 2016

Therapeutic Options in Metastatic CRPC

June 1st 2016

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

June 1st 2016